Affiliation:
1. Department of Breast Surgery The First Affiliated Hospital with Nanjing Medical University Nanjing China
2. Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment Jiangsu Collaborative Innovation Center For Cancer Personalized Medicine School of Public Health Nanjing Medical University Nanjing China
3. Department of Oncology The First Affiliated Hospital with Nanjing Medical University Nanjing China
4. Department of General Surgery Sir Run Run Hospital Nanjing Medical University Nanjing China
5. Pancreas Center & Department of General Surgery The First Affiliated Hospital with Nanjing Medical University Nanjing Jiangsu China
6. Pancreas Institute of Nanjing Medical University Nanjing Jiangsu China
7. Department of Pathology The First Affiliated Hospital with Nanjing Medical University Nanjing China
Abstract
AbstractIntroductionLocoregional recurrent breast cancers have a poor prognosis. Little is known about the prognostic impact of immune microenvironment, and tertiary lymphoid structures (TLSs) in particular have not been reported. Thus, we aimed to characterize the immune microenvironment in locoregional recurrent breast tumors and to investigate its relationship with prognosis.MethodsWe retrospectively included 112 patients with locoregional recurrent breast cancer, and hematoxylin–eosin staining and immunohistochemical staining (CD3, CD4, CD8, CD19, CD38, and CD68) were performed on locoregional recurrent tumor samples. The association of immune cells and TLSs with progression‐free survival (PFS) were analyzed by survival analysis.ResultsWe found more immune cells in the peritumor than stroma. After grouping according to estrogen receptor (ER) status, a low level of peritumoral CD3+ cells in ER+ subgroup (p = 0.015) and a low level of stromal CD68+ cells in ER− subgroup (p = 0.047) were both associated with longer PFS. TLSs were present in 68% of recurrent tumors, and CD68+ cells within TLSs were significantly associated with PFS as an independent prognostic factor (p = 0.035). TLSs and immune cells (CD3, CD38, and CD68) within TLSs were associated with longer PFS in ER− recurrent tumors (p = 0.044, p = 0.012, p = 0.050, p < 0.001, respectively), whereas CD38+ cells within TLSs were associated with shorter PFS in ER+ recurrent tumors (p = 0.037).ConclusionOur study proposes potential predictors for the clinical prognosis of patients with locoregional recurrent breast cancer, emphasizing the prognostic value of immune cells within TLSs, especially CD68+ cells.
Funder
Priority Academic Program Development of Jiangsu Higher Education Institutions
National Natural Science Foundation of China
Subject
Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献